Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) is now available.
Shanghai MicroPort MedBot (Group) Co., Ltd. announced significant changes in its board of directors, with the resignation of Mr. Sun Hongbin, Ms. Fang Cong, and Dr. Li Minghua, who are stepping down to focus on other business commitments. The company has proposed the appointment of Dr. Chang Zhaohua, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, and Ms. Liang Min as new non-executive directors, pending shareholder approval. These changes are expected to bring new perspectives and expertise to the board, potentially impacting the company’s strategic direction and strengthening its position in the medical device industry.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$42.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical device industry, focusing on the development and commercialization of innovative robotic surgical systems. The company is part of the larger MicroPort Scientific Corporation, which is a key player in the medical technology sector.
Average Trading Volume: 6,722,142
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.07B
See more data about 2252 stock on TipRanks’ Stock Analysis page.